Group 1 - The report indicates that Minsheng Securities has effectively reviewed the information disclosure documents of Anhui Wanbang Pharmaceutical Technology Co., Ltd. with no instances of delayed reviews [1] - The company has established and effectively executed relevant regulations, including those to prevent related parties from occupying company resources and managing raised funds [1] - Minsheng Securities conducted monthly checks on the company's fundraising special accounts and confirmed that the progress of fundraising projects aligns with the disclosed information [1] Group 2 - The report states that there were no significant issues identified during the review process, and no measures were required to address any problems [1] - The company and its shareholders have fulfilled their commitments, with no reasons for non-compliance reported [2] - Training was conducted once on April 9, 2025, focusing on disclosure standards [1]
万邦医药: 民生证券股份有限公司关于安徽万邦医药科技股份有限公司2025年半年度持续督导跟踪报告